Edge Therapeutics, $EDGE, a clinical-stage biotech company, today announced fiscal third quarter results. For the financial period ended September 30, 2016, EPS was -$0.37, beating the guidance by $0.03. For the period, cash, cash equivalents and marketable securities were $112.8 million, down from $130.2 million as of December 31, 2015. R&D expenses were $6.7 million for the most recently concluded quarter, compared to $6.5 million for the same period in 2015.